bluuebunny/crossref_metadata_2025_split huggingface dataset:
Pneumococcal 7-Valent Conjugate Vaccine
Authors: Cada Dennis J. , Baker Danial E. , Levien Terri 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The July 2000 Formulary monographs are linezolid, insulin glargine, rivastigmine, pemirolast, and tacrolimus ointment. The DUE is on linezolid.
High Expectations: Standards and Guidelines for Immunization Delivery
Authors: Grabenstein John D. 
Published: January 2018

Credit This lesson if good for 0.2 CE units, with a passing grade of 70%. Objectives After completing this continuing education article, the pharmacist will be able to: 1. Name sources of professional standards for immunization delivery. 2. Describe specific standards related to vaccine administration, record-keeping, and public education. 3. Describe how vaccination standards can be applied to a clinical practice site.
Meloxicam
Authors: Cada Dennis J. , Baker Danial E. , Levien Terri 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The July 2000 Formulary monographs are linezolid, insulin glargine, rivastigmine, pemirolast, and tacrolimus ointment. The DUE is on linezolid.
Avoid Errors with Look-Alike Products Patients Still at Risk of Accidental Intrathecal Vincristine Injection
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute of Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writer's names will be published if desired. ISMP may be contacted at the address shown below.
Chemoprevention of Colorectal Cancer
Authors: Mays-Holland Theresa 
Published: January 2018

Goal After completing this CE program, the participant will understand the basic concepts of chemoprevention and will be able to discuss the currently existing clinical data for the chemoprevention of colorectal cancer. Objectives At the completion of this program the participant will be able to: 1. Discuss the complicating factors in performing chemoprevention trials. 2. Describe the dietary modifications to prevent colorectal cancer. 3. Describe the proposed mechanisms of action of agents used in the chemoprevention of colorectal cancer. 4. Discuss, and where appropriate recommend, appropriate agents for use in the chemoprevention of colorectal cancer. 5. Describe the differences between familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC), and spontaneous adenoma formation.
Design Flaw Predisposes Abbott Lifecare PCA plus II Pump to Dangerous Medication Errors; Folinic Acid: More than a Vitamin; Oral Liquid Medications: More Vulnerable to Errors than Previously Recognized?
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute of Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writer's names will be published if desired. ISMP may be contacted at the address shown below.
Lopinavir/Ritonavir
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The January 2001 Formulary monographs are nateglinide, mitoxantrone, alemtuzumab/campath-1H, galantamine, and levofloxacin. The DUE is on nateglinide.
How to Evaluate a Randomized Controlled Trial: What Every Pharmacist Should Know
Authors: Tsourounis Candy 
Published: January 2018

The primary literature is replete with drug-related-information. The pharmacist is often faced with interpreting and applying this information to clinical practice. Although there are many forms of primary literature, the randomized controlled trial (RCT) is the most commonly used for assessing drug efficacy. This article is designed to review the components of a RCT, including the title, abstract, introduction, methods, results, conclusions, and references. Bias may be introduced into any of these components, either intentionally or unintentionally. Knowing how to evaluate these components will provide pharmacists a framework for interpreting RCT quality. In addition, examples of bias will be provided for each RCT component. Goals (1) to familiarize pharmacists with the components of an RCT; (2) to review sources of RCT bias; and (3) to help pharmacists apply RCT findings to clinical practice. Objectives This article should enable pharmacists to (1) list the components of an RCT; (2) describe five ways bias may be introduced in an RCT; and (3) discuss the limitations and constraints of using an RCT to make clinical decisions.
The Biologics Industry: How Federal Regulation Enhances Quality of Vaccine and Antibody Manufacture
Authors: Grabenstein John D. 
Published: January 2018

Credit — This lesson is good for 0.2 CE units, with a passing grade of 70%. Objectives 1. Describe the historical development of federal regulations that affect manufacture of vaccines and antibodies. 2. Describe the procedures used by the Food and Drug Administration (FDA) to enhance manufacturing quality. 3. List examples of actions FDA may take to deal with substandard products or procedures.
Misuse of Liquid Phosphate Laxatives Used as Bowel Preps
Authors: Pamer Carol A. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute of Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writer's names will be published if desired. ISMP may be contacted at the address shown below.
Put a Stop to Problem-Prone Automatic Stop Order Policies/Pharmacists Should Review All Nonurgent Drug Orders before Administration/Be on Guard for Name Confusion with Two New Medications
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writer's names will be published if desired. ISMP may be contacted at the address shown below.
Insulin Aspart
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The November 2000 Formulary monographs are lopinavir/ritonavir, cetrorelix, fluticasone propionate/salmeterol inhalation powder, atovaquone/proguanil hydrochloride, and exisulind. The DUE is onlopinavir/ritonavir.
Significant Drug–Drug Interactions with Antineoplastics
Authors: May Sondra K. 
Published: January 2018

Goal The goal of this program is to inform the participant about the clinical and economic significance of drug interactions, review their potential mechanisms, present significant interactions related to antineoplastics, and provide resources for managing them. Objectives At the completion of this program, the participant will be able to: 1. Describe the scope and economic impact of preventable drug interactions. 2. Explain why oncology patients are at increased risk for drug interactions. 3. Define the pharmacokinetic, pharmacodynamic, and pharmaceutic principles underlying antineoplastic related drug–drug interactions. 4. List specific classes of antineoplastics involved in significant drug–drug interactions. 5. Identify multiple resources for obtaining drug interaction information.
Side Effects of Vaccination: A Consumer's Guide to Cause and Effect
Authors: Grabenstein John D. 
Published: January 2018

Credit This lesson is good for 0.2 CE units, with a passing grade of 70%. Objectives 1. To describe historical examples of adverse events truly and spuriously associated with vaccination. 2. To describe a rational basis for deciding whether adverse events are causally or coincidentally linked to a medication. 3. To demonstrate how to apply this rational basis to a variety of exposure—outcome associations.
Nebulized Lidocaine Solution for Control of Intractable Cough in a Patient with Metastatic Malignant Melanoma
Authors: Burns Kevin E. 
Published: January 2018

Clinical Pearls Each of these special features conveys an idea, concept, or fact that may be useful in your pharmaceutical practice, but may not be widely known, published, or taught. A 76-year-old male with a diagnosis of metastatic malignant melanoma was experiencing problems with a chronic cough. The cough had initially been managed with guaifenesin with codeine syrup and later with benzonatate capsules, but had become intractable. The patient's paroxysmal coughing resulted in dyspnea, gagging, vomiting, and fatigue—and had a significant impact on the patient's quality of life. The patient was evaluated, and no significant comorbid conditions or drug therapies that might have been aggravating his condition were noted. The patient was evaluated for pharmacologic treatment options. After discussing the pros and cons of each modality, it was decided that nebulized lidocaine would be used as a palliative measure for controlling the patient's intractable cough. A follow-up review of the patient's clinical course revealed that lidocaine was effective in controlling the cough with no adverse consequences.
Methylphenidate Extended-Release Tablets
Authors: Cada Dennis J. , Baker Danial E. , Levien Terri 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The December 2000 Formulary monographs are budesonide inhalation suspension, arsenic trioxide, sodium phosphate, ziprasidone, and unoprostone. The DUE is on budesonide inhalation suspension.
• Orders to “Continue Previous Meds” are a Longstanding Problem/ • More Problems with Verbal Orders/ • FDA Advise-ERR: Dispensing Errors Associated with Zantac and Zyrtec
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—lperhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writer's names will be published if desired. ISMP may be contacted at the address shown below.
Alteplase (t-PA) Bolus: Occluded Catheters
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses ThisHospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. Finally, references direct the reader to the full literature for more comprehensive information prior to patient care decisions.
• Art Imitates Life: Error Portrayal Really Happened/ • Patients with Poor Eyesight Need Extra Help/ • Caution Advised to Prevent Mix-Ups with Sarafem and Serophene
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writer's names will be published if desired. ISMP may be contacted at the address shown below.
Budesonide Inhalation Suspension
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The February 2001 Formulary monographs are iron sucrose injection, oxybate sodium, diclofenac sodium gel, tacrolimus ointment, and docosanol. The DUE is on iron sucrose injection.
• Oral Feeding Formula Confused with Beta-Blocker/• Look-Alike Products from Bedford Laboratories/• Fatal Error with Simultaneous Low-Molecular-Weight and IV Heparins
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again–perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Prevention and Management of Chemotherapy-Induced Nausea and Vomiting, Part 2
Authors: Mullin Shantel , Beckwith M. Christina 
Published: January 2018

Credit This lesson is good for 0.3 CE units, with a passing grade of 70%. Goal The goal of this program is to inform the participant about cost-effective ways to prevent, identify, and manage nausea and vomiting induced by antineoplastic agents. Objectives At the completion of this program the participant will be able to: 1. List antineoplastic agents associated with a high incidence of nausea and vomiting. 2. Identify patient-specific risk factors for developing chemotherapy-induced nausea and vomiting (CINV) and how these factors may influence treatment of this syndrome. 3. Compare the three major types of CINV, including the pathophysiologic mechanism, time of onset, and symptom duration of each type. 4. Explain the mechanism of action and appropriate place in therapy for each type of antiemetic agent. 5. Differentiate between pharmacologic regimens for the prevention and treatment of CINV in adults. 6. Identify drug-specific factors that must be considered when developing a formulary management strategy for the antiemetic agents. 7. Describe specific information that the pharmacist can share with patients to help them understand and manage CINV.